Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Paracrine recruitment and activation of fibroblasts by c-Myc expressing breast epithelial cells through the IGFs/IGF-1R axis.

De Vincenzo A, Belli S, Franco P, Telesca M, Iaccarino I, Botti G, Carriero MV, Ranson M, Stoppelli MP.

Int J Cancer. 2019 Nov 15;145(10):2827-2839. doi: 10.1002/ijc.32613. Epub 2019 Aug 23.

PMID:
31381136
2.

Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells.

Pastorino O, Gentile MT, Mancini A, Del Gaudio N, Di Costanzo A, Bajetto A, Franco P, Altucci L, Florio T, Stoppelli MP, Colucci-D'Amato L.

Cancers (Basel). 2019 May 29;11(6). pii: E747. doi: 10.3390/cancers11060747.

3.

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.

Ragone C, Minopoli M, Ingangi V, Botti G, Fratangelo F, Pessi A, Stoppelli MP, Ascierto PA, Ciliberto G, Motti ML, Carriero MV.

J Exp Clin Cancer Res. 2017 Dec 8;36(1):180. doi: 10.1186/s13046-017-0650-x.

4.

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.

De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S.

Clin Cancer Res. 2015 Nov 15;21(22):5110-20. doi: 10.1158/1078-0432.CCR-15-0375. Epub 2015 Jul 27.

5.

Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.

Bifulco K, Votta G, Ingangi V, Di Carluccio G, Rea D, Losito S, Montuori N, Ragno P, Stoppelli MP, Arra C, Carriero MV.

Oncotarget. 2014 Jun 30;5(12):4154-69.

6.

A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting.

Bifulco K, Longanesi-Cattani I, Liguori E, Arra C, Rea D, Masucci MT, De Rosa M, Pavone V, Stoppelli MP, Carriero MV.

Mol Cancer Ther. 2013 Oct;12(10):1981-93. doi: 10.1158/1535-7163.MCT-13-0077. Epub 2013 Aug 12.

7.

Opposite modulation of cell migration by distinct subregions of urokinase connecting peptide.

Franco P, Carotenuto A, Marcozzi C, Votta G, Sarno C, Iaccarino I, Brancaccio D, De Vincenzo A, Novellino E, Grieco P, Stoppelli MP.

Chembiochem. 2013 May 10;14(7):882-9. doi: 10.1002/cbic.201200774. Epub 2013 Mar 20.

PMID:
23520074
8.

Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.

Bifulco K, Longanesi-Cattani I, Franco P, Pavone V, Mugione P, Di Carluccio G, Masucci MT, Arra C, Pirozzi G, Stoppelli MP, Carriero MV.

PLoS One. 2012;7(9):e44806. doi: 10.1371/journal.pone.0044806. Epub 2012 Sep 25.

9.

RhoB regulates uPAR signalling.

Alfano D, Ragno P, Stoppelli MP, Ridley AJ.

J Cell Sci. 2012 May 15;125(Pt 10):2369-80. doi: 10.1242/jcs.091579. Epub 2012 Feb 24.

10.

Analysis of secretome changes uncovers an autocrine/paracrine component in the modulation of cell proliferation and motility by c-Myc.

Pocsfalvi G, Votta G, De Vincenzo A, Fiume I, Raj DA, Marra G, Stoppelli MP, Iaccarino I.

J Proteome Res. 2011 Dec 2;10(12):5326-37. doi: 10.1021/pr200584y. Epub 2011 Nov 8.

11.

The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.

Carriero MV, Stoppelli MP.

Curr Pharm Des. 2011;17(19):1944-61. Review.

PMID:
21711235
12.

Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors.

Carriero MV, Franco P, Votta G, Longanesi-Cattani I, Vento MT, Masucci MT, Mancini A, Caputi M, Iaccarino I, Stoppelli MP.

Curr Drug Targets. 2011 Nov;12(12):1761-71. Review.

PMID:
21707476
13.

Praf2 is a novel Bcl-xL/Bcl-2 interacting protein with the ability to modulate survival of cancer cells.

Vento MT, Zazzu V, Loffreda A, Cross JR, Downward J, Stoppelli MP, Iaccarino I.

PLoS One. 2010 Dec 20;5(12):e15636. doi: 10.1371/journal.pone.0015636.

14.

The soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequence.

Bifulco K, Longanesi-Cattani I, Gala M, DI Carluccio G, Masucci MT, Pavone V, Lista L, Arra C, Stoppelli MP, Carriero MV.

J Thromb Haemost. 2010 Dec;8(12):2789-99. doi: 10.1111/j.1538-7836.2010.04075.x.

15.

Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor.

Alfano D, Votta G, Schulze A, Downward J, Caputi M, Stoppelli MP, Iaccarino I.

Mol Cell Biol. 2010 Apr;30(7):1838-51. doi: 10.1128/MCB.01442-09. Epub 2010 Feb 1.

16.

Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.

Carriero MV, Longanesi-Cattani I, Bifulco K, Maglio O, Lista L, Barbieri A, Votta G, Masucci MT, Arra C, Franco R, De Rosa M, Stoppelli MP, Pavone V.

Mol Cancer Ther. 2009 Sep;8(9):2708-17. doi: 10.1158/1535-7163.MCT-09-0174. Epub 2009 Aug 25.

17.

Structure, function and antagonists of urokinase-type plasminogen activator.

Vincenza Carriero M, Franco P, Vocca I, Alfano D, Longanesi-Cattani I, Bifulco K, Mancini A, Caputi M, Stoppelli MP.

Front Biosci (Landmark Ed). 2009 Jan 1;14:3782-94. Review.

PMID:
19273310
18.

Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation.

Vocca I, Franco P, Alfano D, Votta G, Carriero MV, Estrada Y, Caputi M, Netti PA, Ossowski L, Stoppelli MP.

Int J Cancer. 2009 Jan 15;124(2):316-25. doi: 10.1002/ijc.23933.

19.

An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor.

Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, Stoppelli MP, Pavone V, Carriero MV.

FEBS Lett. 2008 Apr 2;582(7):1141-6. doi: 10.1016/j.febslet.2008.03.001. Epub 2008 Mar 11.

20.

Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.

Franco P, Vocca I, Carriero MV, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli MP.

J Cell Sci. 2006 Aug 15;119(Pt 16):3424-34. Epub 2006 Aug 1.

21.

Urokinase signaling through its receptor protects against anoikis by increasing BCL-xL expression levels.

Alfano D, Iaccarino I, Stoppelli MP.

J Biol Chem. 2006 Jun 30;281(26):17758-67. Epub 2006 Apr 21.

22.

Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.

Zannetti A, Del Vecchio S, Romanelli A, Scala S, Saviano M, Cali' G, Stoppelli MP, Pedone C, Salvatore M.

Biochem Pharmacol. 2005 Nov 1;70(9):1277-87.

PMID:
16143315
23.

Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.

Gargiulo L, Longanesi-Cattani I, Bifulco K, Franco P, Raiola R, Campiglia P, Grieco P, Peluso G, Stoppelli MP, Carriero MV.

J Biol Chem. 2005 Jul 1;280(26):25225-32. Epub 2005 May 2.

24.

The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.

Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV, Iaccarino I, Stoppelli MP.

Thromb Haemost. 2005 Feb;93(2):205-11. Review.

PMID:
15711734
25.

Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.

Silvestri I, Longanesi Cattani I, Franco P, Pirozzi G, Botti G, Stoppelli MP, Carriero MV.

Int J Cancer. 2002 Dec 20;102(6):562-71.

26.

Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions.

Carriero MV, Franco P, Gargiulo L, Vocca I, Cito L, Fontana L, Iaccarino C, Del Pozzo G, Guardiola J, Stoppelli MP.

Biol Chem. 2002 Jan;383(1):107-13.

PMID:
11928806
27.

Phosphorylation of seminal vesicle protein IV on Ser58 enhances its peroxidase-stimulating activity.

Metafora V, Franco P, Massa O, Morelli F, Stiuso P, Ferranti P, Mamone G, Malorni A, Stoppelli MP, Metafora S.

Eur J Biochem. 2001 Jul;268(13):3858-69.

28.

Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.

Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.

Cancer Res. 2000 Mar 15;60(6):1546-51.

29.

Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.

Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP.

Cancer Res. 1999 Oct 15;59(20):5307-14.

30.

Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.

Chiaradonna F, Fontana L, Iavarone C, Carriero MV, Scholz G, Barone MV, Stoppelli MP.

EMBO J. 1999 Jun 1;18(11):3013-23.

31.
32.

Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist.

Franco P, Massa O, Garcia-Rocha M, Chiaradonna F, Iaccarino C, Correas I, Mendez E, Avila J, Blasi F, Stoppelli MP.

J Biol Chem. 1998 Oct 16;273(42):27734-40.

33.

Vitronectin binding to urokinase receptor in human breast cancer.

Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna F, Botti G, Stoppelli MP, Salvatore M.

Clin Cancer Res. 1997 Aug;3(8):1299-308.

34.

Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility.

Franco P, Iaccarino C, Chiaradonna F, Brandazza A, Iavarone C, Mastronicola MR, Nolli ML, Stoppelli MP.

J Cell Biol. 1997 May 5;137(3):779-91.

35.

Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.

Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M.

Cancer Res. 1994 Oct 15;54(20):5445-54.

36.

In vitro receptor imaging for characterization of human solid tumors.

Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, et al.

Nucl Med Biol. 1994 Jul;21(5):771-4.

PMID:
9241653
37.

Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels.

Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, et al.

Cancer Res. 1993 Jul 1;53(13):3198-206.

38.

Separation and characterization of nonphosphorylated and serine-phosphorylated urokinase. Catalytic properties and sensitivity to plasminogen activator inhibitor type 1.

Franco P, Mastronicola MR, De Cesare D, Nolli ML, Wun TC, Verde P, Blasi F, Stoppelli MP.

J Biol Chem. 1992 Sep 25;267(27):19369-72.

39.

Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells.

Budillon A, Tagliaferri P, Caraglia M, Torrisi MR, Normanno N, Iacobelli S, Palmieri G, Stoppelli MP, Frati L, Bianco AR.

Cancer Res. 1991 Feb 15;51(4):1294-9.

40.

Serine phosphorylation of biosynthetic pro-urokinase from human tumor cells.

Mastronicola MR, Stoppelli MP, Migliaccio A, Auricchio F, Blasi F.

FEBS Lett. 1990 Jun 18;266(1-2):109-14.

41.

Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.

Picone R, Kajtaniak EL, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Danø K, Blasi F.

J Cell Biol. 1989 Feb;108(2):693-702.

42.

An insulin epidermal growth factor-binding protein from Drosophila has insulin-degrading activity.

Garcia JV, Stoppelli MP, Decker SJ, Rosner MR.

J Cell Biol. 1989 Jan;108(1):177-82.

43.

Developmental regulation of an insulin-degrading enzyme from Drosophila melanogaster.

Stoppelli MP, Garcia JV, Decker SJ, Rosner MR.

Proc Natl Acad Sci U S A. 1988 May;85(10):3469-73.

44.

Characterization of a Drosophila protein that binds both epidermal growth factor and insulin-related growth factors.

Garcia JV, Stoppelli MP, Thompson KL, Decker SJ, Rosner MR.

J Cell Biol. 1987 Jul;105(1):449-56.

45.

The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.

Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F.

J Biol Chem. 1987 Apr 5;262(10):4437-40.

46.

Autocrine saturation of pro-urokinase receptors on human A431 cells.

Stoppelli MP, Tacchetti C, Cubellis MV, Corti A, Hearing VJ, Cassani G, Appella E, Blasi F.

Cell. 1986 Jun 6;45(5):675-84.

PMID:
3011276
47.
48.

The receptor for urokinase-plasminogen activator.

Blasi F, Stoppelli MP, Cubellis MV.

J Cell Biochem. 1986;32(3):179-86. Review.

PMID:
3023408
49.

Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.

Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK.

Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939-43.

50.

Transcriptional induction of urokinase in cultured human kidney carcinoma cells by tetradecanoyl-phorbol-acetate.

Ferraiuolo R, Stoppelli MP, Verde P, Bullock S, Lazzaro P, Blasi F, Pietropaolo TC.

J Cell Physiol. 1984 Nov;121(2):368-74.

PMID:
6386832

Supplemental Content

Loading ...
Support Center